Clinical trials: Immune Checkpoint Inhibitors
Arrhythmia, Long QT Syndrome
AI-powered ECG Analysis for Deadly Arrhythmias and ICI Myocarditis
ELDORA is a non-interventional observational data-science study aiming to develop and validate clinical-grade artificial intelligence tools applied to electrocardiogram (ECG) data.
- Conditions
- Arrhythmia, Long QT Syndrome, Immune Checkpoint Inhibitor-Related Myocarditis
- Trial name
- ELDORA (NCT07644715)
- Where
- France
- Volunteers
- 127,000 people, healthy volunteers welcome
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
Cancer, Immune-related Adverse Event
EXploring Immune-related Adverse Events of Immune checkpoinT Inhibitors Using VigiBase, the WHO Pharmacovigilance Database
This is an observational, retrospective pharmacovigilance study based on reports registered and transmitted in VigiBase®, the WHO's international database.
- Conditions
- Cancer, Immune-related Adverse Event, Immune Checkpoint Inhibitor-Related Myocarditis
- Trial name
- EXIT (NCT05934214)
- Testing
- Immune checkpoint inhibitor
- Where
- 2 sites in France
- Volunteers
- 141,630 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
HCC
Nimotuzumab Combined With ICIs for the Treatment of Advanced Liver Cancer After First Line Treatment Failure
This is a phase II, open-label, single-arm clinical study of nimotuzumab in combination with immune checkpoint inhibitors in patients with advanced liver cancer who have failed first-line therapy
- Trial name
- NCT06413017
- Testing
- Nimotuzumab, ICIs(Immune checkpoint inhibitors)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Cutaneous Toxicity From ICI Therapy
Analysis of Reporting of Cutaneous Toxicities Associated With Immune Checkpoint Inhibitors
Immune checkpoint inhibitors (ICIs) are associated with a wide variety of cutaneous immune-related adverse events (cirAEs). These cirAEs are reported to be the most common immune-related adverse events (irAEs) and the first to…
- Trial name
- NCT04898751
- Testing
- Immune checkpoint inhibitor (ICI)
- Where
- United States
- Volunteers
- 2,214 people
- Sponsor
- Johns Hopkins University
Immune Checkpoint Inhibitor-associated Myocarditis
ATROPOS: Survival Analysis of ICI-associated Myocarditis
ATROPOS is an international, registry-based observational study of cancer patients with immune checkpoint inhibitor-associated myocarditis (ICI-M).
- Trial name
- ATROPOS (NCT07633587)
- Where
- France
- Volunteers
- 1,500 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
Gastric Cancer
Real World Study of Immune Checkpoint Inhibitors for Advanced Gastric Cancer
Gastric cancer ranks as the fifth most common and the third most common cause of cancer deaths in the world. In spite of the progresses made in the diagnosis and treatment of gastric cancer in the past decades, the prognosis is…
- Trial name
- NCT04086888
- Where
- 2 sites in China
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- Sun Yat-sen University
Patients Recieving Anti-PD-1 or Anti-PD-L1 Immunotherapies
Impact of Immune Checkpoint Inhibitor Therapy on Type 2 Inflammation
The primary objective of this study is to determine the impact of anti-checkpoint immunotherapy on type 2 inflammation via a retrospective analysis of % eosinophilia.
- Trial name
- ImmunEO (NCT04609930)
- Testing
- Anti-PD-1 or anti-PD-L1
- Where
- France
- Volunteers
- 143 people
- Sponsor
- University Hospital, Montpellier
mRNA Vaccination, Hepatocellular Carcinoma
SARS-CoV-2 mRNA Vaccination in Patients With Hepatocellular Carcinoma Treated With Immune Checkpoint Inhibitors
A multicenter retrospective cohort analysis in Austria Primary Objective: To assess whether receiving an mRNA COVID-19 vaccine within 3 months before starting ICI (Immune checkpoint inhibitors) therapy improves best overall…
- Conditions
- mRNA Vaccination, Hepatocellular Carcinoma, Checkpoint Inhibitor
- Trial name
- CoVaCheck (NCT07341321)
- Where
- 5 sites in Austria
- Volunteers
- 200 people
- Sponsor
- Medical University of Graz
Metastatic Melanoma
Power of Liquid Biopsy Tracking in Immunotherapy Treated Stage IV Melanoma
The advent of immune ICI has remarkably improved survival in advanced melanoma patients in the last decade. Long term responders following 2 years of treatment with immunotherapy go on to surveillance with frequent radiological…
- Trial name
- PerceIVe (NCT06710093)
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Metastatic Uveal Melanoma
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
The purpose of this study is to measure the clinical benefits of the combination of RP2 and nivolumab as compared with the combination of nivolumab and ipilimumab in patients with metastatic uveal melanoma who have not been…
- Trial name
- NCT06581406
- Testing
- RP2, Ipilimumab, Nivolumab
- Where
- 33 sites in United States, Australia and 1 more
- Volunteers
- 280 people
- Sponsor
- Replimune, Inc.
Immune Checkpoint Inhibitor-Induced Dermatitis, Stevens-Johnson Syndrome, Drug-Induced
SJS/TEN or Other Cutaneous Adverse Eevents Induced by Immune Checkpoint Inhibitors (ICIs) vs. Non-ICIs
Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) is a severe adverse drug reaction, characterized by extensive skin detachment.
- Conditions
- Immune Checkpoint Inhibitor-Induced Dermatitis, Stevens-Johnson Syndrome, Drug-Induced, Toxic Epidermal Necrolysis Due to Drug
- Trial name
- NCT06522048
- Testing
- Observational studies do not require intervention
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Chao Ji
Lung Cancer, Nonsmall Cell, Renal Cell Carcinoma
Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity
"Risk factors of Immune-ChEckpoint inhibitor MEdiated Liver, gastrointestinal, endocrine and skin Toxicity" (ICEMELT) study is a prospective multicenter cohort study, enrolling patients who are scheduled to receive (1) single…
- Conditions
- Lung Cancer, Nonsmall Cell, Renal Cell Carcinoma, Melanoma, Gastric Cancer
- Trial name
- ICEMELT (NCT04631731)
- Testing
- Blood screening, Tissue screening
- Where
- 2 sites in Australia
- Volunteers
- 200 people
- Sponsor
- Western Sydney Local Health District
Gastric Cancer Stage IV
Conversion Surgery After Target Therapy or Immunotherapy in Stage IV Gastric Cancer
In this retrospective study, investigators conducted a comprehensive investigation of the factors influencing postoperative prognosis in patients with stage IV gastric cancer undergoing conversion surgery.
- Trial name
- NCT07009600
- Testing
- immune check point inhibitors (PD-1 inhibitors), target therapy (trastuzumab)
- Volunteers
- 124 people
- Sponsor
- Samsung Medical Center